ADVERTISEMENT
Subscribe
Menu
Login
Login
Subscribe
News & Opinion
Publications
AN INTERACTIVE EXPERIENCE
Current Issue
February 2023
Preview This Issue
Archives
Features
Quarterly Magazine
Current Issue
Winter 2022
Preview This Issue
Archives
Features
Categories
Biochemistry
Cancer
Cell Biology
Community
Drug Development
Environment
Evolution
Genetics
Immunology
Microbiology
Neuroscience
Physiology
Public Health
Zoology
TS University
Scientific Services
Brush Up Summaries
Technique Talks
Journal Club
Multimedia
Crossword Puzzles
eBooks
Infographics
Podcasts
Research Products Blog
Research Articles
Science Snapshot
Slideshows
Videos
Words for Nerds
Webinars
ADVERTISEMENT
Two Children Die After Receiving Novartis Gene Therapy
No deaths had previously been associated with the muscle-wasting treatment Zolgensma.
Two Children Die After Receiving Novartis Gene Therapy
Two Children Die After Receiving Novartis Gene Therapy
No deaths had previously been associated with the muscle-wasting treatment Zolgensma.
No deaths had previously been associated with the muscle-wasting treatment Zolgensma.
Home
Subjects
spinal muscular atrophy
spinal muscular atrophy
Concerns over Efficacy and Cost of Muscle Wasting Treatments
Ruth Williams
| Nov 11, 2020
| 5 min read
Two new medications for treating a rare and deadly neuromuscular disease have high prices and questionable efficacies, say scientists.
Lottery Underway for Rare Muscle-Wasting Disease Gene Therapy
Lisa Winter
| Jan 7, 2020
| 2 min read
The announcement by Novartis, the maker of Zolgensma, has drawn mixed reactions from the spinal muscular atrophy community.
Fetal Gene Therapy Helps Mice with Spinal Muscular Atrophy
Alejandra Manjarrez, PhD
| Dec 11, 2019
| 4 min read
The animals lived longer and showed milder symptoms than untreated mice, although they didn’t survive as long as wildtype mice.
FDA Approves Gene Therapy for Spinal Muscular Atrophy
Ashley Yeager
| May 27, 2019
| 3 min read
At $2 million for a single dose, Novartis’s Zolgensma is the most expensive medicine to date, but still less expensive over a lifetime than another approved drug for the rare genetic disease.
ADVERTISEMENT